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Background
New prevention options will be added to the 'standard of
prevention' offered in HIV vaccine efficacy trials as new
methods prove effective. The HVTN503/Phambili trial
was initiated in January 2007, shortly after results from 3
randomized controlled trials of male circumcision (MC)
demonstrated that MC reduces the risk of HIV acquisition.
Thus, HVTN503 investigators made plans to offer MC at
no cost to enrolled male participants.
Methods
All participants were informed of the benefits of MC as a
component of HIV risk reduction counseling, including
how and where MC could be accessed. One site offered
on-site MC and the others provided referral to local serv-
ices for men who requested MC. We present data on
uptake of MC post-enrollment.
Results
Prior to discontinuation of enrolment, 441 men joined
the trial, of whom 312 (70.7%) were uncircumcised. Of
these, 82 (26.3% of uncircumcised men) requested MC
after enrolment. Uptake varied by site, being lower
(<15%) at the Medunsa and KOSH sites, intermediate at
Soweto and Cape Town sites, and high (>70%) at the
eThekwini site, the site with lowest baseline MC preva-
lence. Among 3 sites with intermediate baseline MC prev-
alence, uptake varied from 3.3 to 37.6%, being highest at
the site providing MC on site. Uptake was similar in vac-
cine and placebo arms of the trial [42 (26.1%) vs. 40
(26.5%)]. There was no significant difference by arm in
the timing of circumcision relative to randomization
assignment being provided to participants following
release of the STEP trial results [post-unblinding, vaccine
18 (42.9%) vs. placebo 13 (32.5%), p = 0.37].
Conclusion
MC, a new prevention modality, was offered as part of
HIV prevention services in HVTN503. Uptake varied by
provision of care model and inversely with baseline MC
prevalence, but did not differ between treatment arms,
and remained similar even after provision of treatment.
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